A British cancer charity is to fund clinical trials of a drug owned by GlaxoSmithKline in a pioneering programme to develop promising experimental medicines that are neglected because of limited corporate funding.
Cancer Research Technology, the commercial arm of Cancer Research UK, will shortly begin tests in patients of GSK's 1070916A, and retain a share of the profits if the drug is successfully launched.
